Open AccessOncology Drug Discovery Applications Using the FMAT™ 8100 HTS System
Author(s) -
Jennifer Y. Lee,
Sheri Miraglia,
Xiongwei Yan,
Elana Swartzman,
Susan Cornell-Ken,
Julia Mellentin-Michelotti,
Charles W. Bruseo
Publication year - 2003
Publication title -
slas discovery
Language(s) - English
Resource type - Journals
eISSN - 2472-5560
pISSN - 2472-5552
DOI - 10.1177/1087057102239668
Subject(s) - drug discovery , homogeneous , annexin , high throughput screening , tyrosine kinase , peptide , computational biology , chemistry , microbiology and biotechnology , biochemistry , biology , cell , signal transduction , physics , thermodynamics
High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT™ 8100 HTS System) in three distinct homogeneous HTS assays: (1) a Src tyrosine kinase enzyme assay, (2) a Grb2-SH2 protein-peptide interaction assay, and (3) an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens. ( Journal of Biomolecular Screening 2003:81-88)